# US 2019/0209668 A1 · Treatment of canine atopic dermatitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0209668 A1
- Document ID: US20190209668A1
- Status: Published application
- Kind: A1
- Application number: 16/097,156
- Filed: 2017-04-26
- Published: 2019-07-11
- Earliest claimed: 2016-04-27
- Assignees: Benchmark Animal Health Limited
- Applicants: Benchmark Animal Health Ltd.
- Inventors: Kaspars TARS
- Web page: https://patentgrep.com/patent/US20190209668A1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/12: Viral antigens
- A61K 39/35: Allergens
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/005: from viruses
- C07K 14/08: RNA viruses
- C07K 16/244: {Interleukins [IL]}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2760/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/00023: Virus like particles [VLP]
- C12N 2760/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/14022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/14023: Virus like particles [VLP]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of canine atopic dermatitis (CAD). Furthermore, the invention provides methods for preventing or treating CAD. The compositions of the invention induce efficient immune responses, in particular antibody responses, in dogs and are, therefore, useful for the treatment and/or prevention of CAD.

## Claims

### Claim 1

A composition for use in a method of preventing or treating canine atopic dermatitis (CAD) of a canidae, preferably of a domestic dog, wherein an effective amount of said composition is administered to said canidae, preferably to said domestic dog, and wherein said composition comprises
(a) a core particle with at least one first attachment site; and
(b) at least one canine Interleukin-31 antigen (cIL-31 antigen) with at least one second attachment site, wherein said cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from SEQ ID NO:22 or a protein with an amino acid sequence of at least 90%, preferably of at least 92%, further preferably of at least 95%, and again further preferably of at least 98% amino acid sequence identity with SEQ ID NO:22;
wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.

### Claim 2

The composition for use of any one of the preceding claims, wherein said core particle is a virus-like particle (VLP), preferably a recombinant VLP.

### Claim 3 (depends on 2)

The composition for use of claim 2, wherein said VLP is derived from a plant virus.

### Claim 4 (depends on 2, 3)

The composition for use of any one of the claims 2 to 3, wherein said VLP is a modified VLP comprising, essentially consisting of, or alternatively consisting of, at least one modified VLP polypeptide, wherein said modified VLP polypeptide comprises, or preferably consists of,
(a) a VLP polypeptide, and
(b) a T helper cell epitope,
wherein said VLP polypeptide comprises, or preferably consists of,
(i) an amino acid sequence of a coat protein of a virus, preferably an amino acid sequence of a coat protein of a plant virus; or
(ii) a mutated amino acid sequence, wherein the amino acid sequence to be mutated is an amino acid sequence of said coat protein of a virus, and wherein said mutated amino acid sequence and said coat protein of a virus show a sequence identity of at least 90%, preferably of at least 95%, further preferably of at least 98% and again more preferably of at least 99%.

### Claim 5 (depends on 2, 3, 4)

The composition for use of any one of the claims 2 to 4, wherein said VLP is a modified VLP of cucumber mosaic virus (CMV), wherein said modified VLP of CMV comprises, essentially consists of, or alternatively consists of, at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises, or preferably consists of,
(a) a CMV polypeptide, and
(b) a T helper cell epitope; and
wherein said CMV polypeptide comprises, or preferably consists of,
(ii) an amino acid sequence of a coat protein of CMV; or
(ii) a mutated amino acid sequence, wherein the amino acid sequence to be mutated is an amino acid sequence of a coat protein of CMV, and wherein said mutated amino acid sequence and said coat protein of CMV show a sequence identity of at least 90%, preferably of at least 95%, further preferably of at least 98% and again more preferably of at least 99%.

### Claim 6 (depends on 5)

The composition for use of claim 5, wherein said CMV polypeptide comprises, or preferably consists of,
(a) an amino acid sequence of a coat protein of CMV, wherein said amino acid sequence comprises, or preferably consists of, SEQ ID NO:1 or
(b) an amino acid sequence having a sequence identity of at least 90% of SEQ ID NO:1; and
wherein said amino sequence as defined in (a) or (b) in this claim comprises SEQ ID NO:23; or
wherein said amino sequence as defined in (a) or (b) in this claim comprises an amino acid sequence region, wherein said amino acid sequence region has a sequence identity of at least 90% with SEQ ID NO:23.

### Claim 7 (depends on 5, 6)

The composition for use of any one of the claims 5 to 6, wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, and wherein said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:1.

### Claim 8 (depends on 5, 6, 7)

The composition for use of any one of the claims 5 to 7, wherein said Th cell epitope is a PADRE sequence, and wherein said Th cell epitope comprises, preferably consists of, the amino acid sequence of SEQ ID NO:5; or wherein said Th cell epitope is derived from tetanus toxin, and wherein said Th cell epitope has, preferably consists of, the amino acid sequence of SEQ ID NO:4.

### Claim 9 (depends on 5, 6, 7, 8)

The composition for use of any one of the claims 5 to 8, wherein said CMV polypeptide comprises, or preferably consists of, an amino acid sequence of a coat protein of CMV, wherein said amino acid sequence comprises, or preferably consists of, SEQ ID NO:1 or an amino acid sequence having a sequence identity of at least 95% of SEQ ID NO:1;
and wherein said amino sequence comprises SEQ ID NO:23, and wherein said T helper cell epitope replaces the N-terminal region of said CMV polypeptide, and wherein said replaced N-terminal region of said CMV polypeptide consists of 11 to 13 consecutive amino acids, preferably of 11 consecutive amino acids, and wherein further preferably said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:1.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The composition for use of any one of the claims 5 to 9, wherein said modified CMV polypeptide comprises, preferably consists of, an amino acid sequence of SEQ ID NO:6 or SEQ ID NO:7.

### Claim 11

The composition for use of any one of the preceding claims, wherein said at least one cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from:
(a) SEQ ID NO:18;
(b) SEQ ID NO:21;
(c) SEQ ID NO:22; or
(d) SEQ ID NO:26.

### Claim 12

The composition for use of any one of the preceding claims, wherein said administration of said composition reduces at least one CAD parameter or symptom as compared to said at least one CAD parameter or symptom before said administration, and wherein preferably said at least one CAD parameter or symptom is the level or severity grade of skin lesions or itching, and wherein further preferably said reduction of said level or severity grade of skin lesions is determined by a symptom and lesion scoring test.

### Claim 13

A composition comprising
(a) a virus-like particle (VLP) with at least one first attachment site;
(b) at least one canine Interleukin-31 antigen (cIL-31 antigen) with at least one second attachment site, wherein said cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from SEQ ID NO:22 or a protein with an amino acid sequence of at least 90%, preferably of at least 92%, further preferably of at least 95%, and again further preferably of at least 98% amino acid sequence identity with SEQ ID NO:22, and again further preferably said antigen comprises, or preferably consists of a protein with the amino sequence of SEQ ID NO:22;
wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.

### Claim 14 (depends on 13, 14)

The composition of claim 13 or 14, wherein said VLP is a modified VLP of cucumber mosaic virus (CMV), wherein said modified CMV polypeptide comprises, preferably consists of, an amino acid sequence of SEQ ID NO:6 or SEQ ID NO:7.

### Claim 15 (depends on 13, 14)

The composition of claim 13 or 14, wherein said second attachment site is a sulfhydryl group, and wherein preferably said sulfhydryl group is derived from reaction of said cIL-31 antigen with N-succinimidyl S-acetylthioacetate (SATA), and wherein preferably said said at least one cIL-31 antigen comprises, or preferably consists of, a protein with the amino sequence selected from:
(a) SEQ ID NO:18;
(b) SEQ ID NO:21;
(c) SEQ ID NO:22; or
(d) SEQ ID NO:26.
